Heparin - Adverse effects
Research News and Information

Sunday, November 22, 2009

Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.

27 Sep 2009 OBJECTIVES: We assessed the incidence, predictors, and outcomes of gastrointestinal bleeding (GIB) in patients with acute coronary syndromes (ACS). BACKGROUND: GIB is a potential hemorrhagic complication in patients with ACS treated with ... Read more...

Incidence and causes of heparin-induced skin lesions.

26 Sep 2009 BACKGROUND: Little is known about the incidence and causes of heparin-induced skin lesions. The 2 most commonly reported causes of heparin-induced skin lesions are immune-mediated heparin-induced thrombocytopenia and delayed-type hypersensitivity ... Read more...

[Anesthetic management for a patient with heparin-induced thrombocytopenia (HIT) undergoing off-pump coronary bypass surgery using argatroban, a direct thrombin inhibitor]

30 Aug 2009 HIT type II is one of the severe complications of heparin therapy. The antibody for the heparin-PF 4 complex, which causes thrombocytopenia of less than 100 x 10(3) microl(-1), thrombosis and DIC-like symptoms, is produced. We managed the patient ... Read more...

Latest indexed articles for 'Heparin - Adverse effects'

These are the very latest articles for this heading:

• Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. 27 Sep 2009
• Incidence and causes of heparin-induced skin lesions. 26 Sep 2009
• [Anesthetic management for a patient with heparin-induced thrombocytopenia (HIT) undergoing off-pump coronary bypass surgery using argatroban, a direct thrombin inhibitor] 30 Aug 2009
• Oldies but goodies. 30 Aug 2009
• Impact of bivalirudin on in-hospital bleeding and six-month outcomes in octogenarians undergoing percutaneous coronary intervention. 30 Aug 2009
• Heparin induced thrombocytopenia and re-thrombosis associated with warfarin and fondaparinux in a child. 30 Aug 2009
• Splenic infarction and subsequent splenic rupture in a patient with paroxysmal nocturnal hemoglobinuria and heparin-induced thrombocytopenia. 30 Aug 2009
• Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. 26 Aug 2009
• The changing horizon of acute coronary syndrome. 26 Aug 2009
• [Case of anosmia which appeared after anaphylactic shock due to intravenous heparin] 30 Jul 2009
• Hemostatic effectiveness of a new application method for fibrin glue, the "rub-and-spray method", in emergency aortic surgery for acute aortic dissection. 30 Jul 2009
• Impact of chronic kidney disease on early (30-day) and late (1-year) outcomes of patients with acute coronary syndromes treated with alternative antithrombotic treatment strategies: an ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) substudy. 30 Jul 2009
• Subcutaneous heparin for prophylaxis of venous thromboembolism in deep brain stimulation surgery: evidence from a decision analysis. 30 Jul 2009
• Heparin allergy: delayed-type non-IgE-mediated allergic hypersensitivity to subcutaneous heparin injection. 30 Jul 2009
• Clinical and economic outcomes in patients at risk of venous thromboembolism receiving appropriate enoxaparin or unfractionated heparin prophylaxis. 30 Jul 2009
• A comparison of anticoagulation with bivalirudin and provisional GPIIb/IIIa inhibition with unfractionated heparin and mandatory GPIIb/IIIa inhibition during percutaneous coronary intervention in relation to platelet activation and the inhibition of coagulation. 30 Jul 2009
• Safety and efficacy of a prolonged bivalirudin infusion after urgent and complex percutaneous coronary interventions: a descriptive study. 30 Jul 2009
• Thrombocytopenia and other hot topics. 30 Jul 2009
• HeartMate II implantation in patients with heparin-induced thrombocytopenia type II. 30 Jul 2009
• Management of acquired bleeding problems in cancer patients. 30 Jul 2009

See a longer list of these articles.

Technical information about 'Heparin'

Definition: A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts.

Registry Number: 9005-49-6

Descriptor UI: D006493

Alternative terms: Heparin; Heparinic Acid; Liquaemin; Sodium Heparin; Heparin, Sodium; Heparin Sodium; alpha-Heparin; alpha Heparin;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; deficiency; diagnostic use; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists; ultrastructure;

Pharmacological Action: Fibrinolytic Agents; Anticoagulants;

Tree Number: D09.698.373.400;

History Note: /therapeutic use was HEPARIN, THERAPEUTIC 1965